Skip to main content

Author: ParadigMS Foundation

New publication by ParadigMS Experts: Navigating generics, biosimilars, and NBCDs in MS

We’re proud to share a recent publication authored by ParadigMS experts, now featured in the European Journal of Neurology:“Generics, biosimilars and follow‐on non‐biologic complex drugs for Multiple Sclerosis: A narrative review of the regulatory and clinical implications for European neurologists.” The review examines the growing presence of generics, biosimilars, and follow-on non-biologic complex drugs (NBCDs) in multiple sclerosis care, outlining the regulatory landscape and the practical implications for clinical practice in Europe. Highlights include: Clear distinctions between...

Continue reading

Advancing patient-centered neurology: insights from Professor Patrick Vermersch, ParadigMS Foundation board member

We are proud to highlight the work of Professor Patrick Vermersch, ParadigMS Board Member and Director of the Graduate School for Biology and Health at the University of Lille.Throughout his career, Professor Vermersch has made outstanding contributions to the fields of Multiple Sclerosis (MS) and neurodegenerative disease research. From early studies on Tau proteins in Alzheimer’s and Parkinson’s disease to groundbreaking work in MS biomarkers and treatment strategies, his research has consistently pushed the boundaries of neurology. He played a leading role in establishing a specialized...

Continue reading

Collaborating for Progress in MS Care

On Saturday, 29th March, a dynamic group of ParadigMS board members gathered online for an expert meeting focused on advancing clinical practice and research in multiple sclerosis. The agenda featured detailed presentations and open discussions on critical and emerging themes—from the integration of AI in MS care pathways to new perspectives on B-cell therapies and subtle disease progression. Chaired by ParadigMS President Prof. Celia Oreja-Guevara, the meeting highlighted: Finalised and new data on body fluid markers, AI in clinical pathways, and B-cell therapies Practical updates...

Continue reading

New publication on pseudotumoral lesions in MS co-authored by Prof. Jelena Drulovic

Prof. Jelena Drulovic, ParadigMS Foundation Board Member, has co-authored the article Etiology and Characteristics of Pseudotumoral Lesions and Tumefactive Demyelination in Multiple Sclerosis, published in Elsevier in November 2024. We are pleased to invite you to explore this publication, which provides valuable insights into the complexities of pseudotumoral MS lesions and their clinical implications. Introduction The article titled “Etiology and Characteristics of Pseudotumoral Lesions and Tumefactive Demyelination in Multiple Sclerosis” delves into the complex nature...

Continue reading

ParadigMS Expert Prof. Magd Zakaria co-authors study on predicting disease activity in relapsing-remitting MS

We are delighted to share a new article Development and Validation of a Scoring System for Predicting Disease Activity in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis co-authored by Prof. Magd Zakaria, a ParadigMS Foundation Board Member. This collaborative research, published in the journal Multiple Sclerosis and Related Disorders (MSARD Journal) on 16th January 2025, highlights significant findings that contribute to the growing body of knowledge on prognosis in multiple sclerosis (MS) management. Introduction Relapsing-remitting multiple sclerosis (RRMS) presents...

Continue reading

2024: ParadigMS for Multiple Sclerosis Care

Dear colleagues, supporters, and friends, As 2024 ends, we celebrate a year of progress at ParadigMS, marked by impactful events like the Belgian Symposium, the International Neuroimmunology Conference and the Pre-MENACTRIMS Symposium. These achievements reflect our shared commitment to advancing MS care and education worldwide. Looking ahead to 2025, we are excited to launch initiatives focused on emerging therapies, advanced diagnostics, and practical tools to empower healthcare professionals. Together, we will continue to drive meaningful improvements in MS management. We also mourn...

Continue reading

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.